Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Arterial Infusion Chemotherapy and Immunotherapy (HAICI) as Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma in BCLC A/B Stage Beyond Up to Seven Criteria: An Open-Label, Single-Arm, Pilot Study

NCT06741020 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT06741020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06741020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Arterial Infusion Chemotherapy and Immunotherapy (HAICI) as Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma in BCLC A/B Stage Beyond Up to Seven Criteria: An Open-Label, Single-Arm, Pilot Study
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 1, 2025
Completion date
December 30, 2026
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)